Susan Hasty, Publisher
Table of Contents . . . June 10th, 2002Non-Subscriber - Summaries Only
Chronic Hepatitis B - Combination of vaccine and antiviral fractures immune tolerance in virus model
Combination Therapy - RNA levels at 12 weeks best indicator for sustained response in hepatitis C
Osteoporosis - Vitamin K-2 prevents bone loss in women with cirrhosis
End-stage Liver Disease - Potential therapy reported for children, adults
Finance - First quarter net loss: $0.09 per share
Mergers and Acquisitions - Dimethaid Research completes purchase agreement for Oxo Chemie AG
Mergers and Acquisitions - Dragon Acquires Remainder of Nanjing Huaxin Biopharmaceutical Co.
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.